Scholarlink

Introduction <p>Frailty assessment is fundamental to geriatric oncology (GO), with GO guidelines endorsing Geriatric-8 (G8) as a frailty screening tool. Although the Clinical Frailty Scale (CFS) is widely used in geriatrics, no studies have examined its quality of life (QoL) utility in GO. We compare CFS and G8 in their ability to predict quality of life among older adults receiving curative cancer treatment.</p> Patients and methods <p>One hundred thirteen patients (age ≥ 65 years) were recruited from a 2000-bed university-affiliated tertiary hospital between August 2020 and May 2024. Patient demographics, CFS and G8 were collected. The EORTC QLQ-ELD14 and the EQ5D-VAS were measured at start of treatment, and monthly after for 3 months. Patients were stratified by CFS or G8 and compared with QoL at various time points controlled for age, gender, BMI, and G8.</p> Results <p>Using CFS, frail subjects had&#xa0;poorer QoL in the EORTC QLQ-ELD14 subscales for mobility (<i>p</i> &lt; 0.001), joint stiffness (<i>p</i> &lt; 0.001), maintaining purpose (<i>p</i> = 0.03), and EQ5D-VAS (<i>p</i> = 0.003) at start of&#xa0;treatment; mobility (<i>p</i> = 0.004 and <i>p</i> = 0.009) and EQ5D-VAS (<i>p</i> = 0.03 and <i>p</i> = 0.009) scores at one and 2 months. QoL scores between groups were similar at 3 months. Using G8, only EQ5D-VAS was poorer for frail subjects at start of treatment (<i>p</i> = 0.02). CFS remained a significant indicator of poor QoL controlled for age, gender, BMI, and G8.</p> Conclusion <p>CFS is a significant and better indicator of poor QoL in older adults with cancer receiving curative treatment compared to G8. Further research should explore implementation of supportive care for specific QoL deficit detected by CFS.</p> <p>Trial registration: NCT04513977; Date 2020–08-14.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Frailty Scale versus Geriatric-8 in predicting quality of life among older adults receiving curative cancer treatment

  • 期刊论文

  • 发表日期：

    2025年6月6日

查看全文
  • Wen Yang Goh,
  • Hui Min Tan,
  • Hui Lin Teo,
  • Elise K. Y. Vong,
  • Francis C. H. Ho,
  • Ming Yann Lim,
  • Allyn Y. M. Hum

摘要

Introduction

Frailty assessment is fundamental to geriatric oncology (GO), with GO guidelines endorsing Geriatric-8 (G8) as a frailty screening tool. Although the Clinical Frailty Scale (CFS) is widely used in geriatrics, no studies have examined its quality of life (QoL) utility in GO. We compare CFS and G8 in their ability to predict quality of life among older adults receiving curative cancer treatment.

Patients and methods

One hundred thirteen patients (age ≥ 65 years) were recruited from a 2000-bed university-affiliated tertiary hospital between August 2020 and May 2024. Patient demographics, CFS and G8 were collected. The EORTC QLQ-ELD14 and the EQ5D-VAS were measured at start of treatment, and monthly after for 3 months. Patients were stratified by CFS or G8 and compared with QoL at various time points controlled for age, gender, BMI, and G8.

Results

Using CFS, frail subjects had poorer QoL in the EORTC QLQ-ELD14 subscales for mobility (p < 0.001), joint stiffness (p < 0.001), maintaining purpose (p = 0.03), and EQ5D-VAS (p = 0.003) at start of treatment; mobility (p = 0.004 and p = 0.009) and EQ5D-VAS (p = 0.03 and p = 0.009) scores at one and 2 months. QoL scores between groups were similar at 3 months. Using G8, only EQ5D-VAS was poorer for frail subjects at start of treatment (p = 0.02). CFS remained a significant indicator of poor QoL controlled for age, gender, BMI, and G8.

Conclusion

CFS is a significant and better indicator of poor QoL in older adults with cancer receiving curative treatment compared to G8. Further research should explore implementation of supportive care for specific QoL deficit detected by CFS.

Trial registration: NCT04513977; Date 2020–08-14.